[11C]choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: Preliminary results of a prospective study

Urologia Internationalis

Volumn 81, Issue 2, 2008, Pages 191-197

  Rinnab, Ludwig ^a   Mottaghy, Felix M ^a,b   Simon, Joerg ^a   Volkmer, Bjoern G ^a   De Petriconi, Robert ^a   Hautmann, Richard E ^a   Wittbrodt, Markus ^c   Egghart, Guenther ^c   Moeller, Peter ^a   Blumstein, Norbert ^a   Reske, Sven ^a   Kuefer, Rainer ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c District Hospital Sigmaringen   (Germany)

Author keywords

11C choline PET CT; Prostate cancer; Rising prostate specific antigen; Salvage lymph node dissection

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER; CHOLINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SALVAGE THERAPY; BLOOD; COMPARATIVE STUDY; LYMPHADENECTOMY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; TUMOR RECURRENCE;

AGED; BIOLOGICAL MARKERS; CHOLINE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 50849135142     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000144059     Document Type: Article

References (33)

1. Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993;41:113-120.
2. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-659.
3. Scattoni V, Roscigno M, Raber M, et al: Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003;44:407-414.
4. Sella T, Schwartz LH, Swindle PW, et al: Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-385.
5. Cher ML, Bianco FJ Jr, Lam JS, et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-1391.
6. Hara T, Kosaka N, Kishi H: PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-995.
7. DeGrado TR, Baldwin SW, Wang S, et al: Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-1814.
8. Scheidler J, Hricak H, Vigneron DB, et al: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging: clinicopathologic study. Radiology 1999;213:473-480.
9. Yu KK, Hricak H: Imaging prostate cancer. Radiol Clin North Am 2000;38:59-85, viii.
10. Rodriguez-Gonzalez A, Ramirez de Molina A, Benitez-Rajal J, Lacal JC: Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003;5:191-201.
11. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al: Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-583.
12. 11C]choline: implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
13. Rinnab L, Blumstein NM, Mottaghy FM, et al: (11)C-choline positron-emission tomography/ computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99:1421-1426.
14. Wilson AA, Garcia A, Jin L, Houle S: Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 2000;27:529-532.
15. Farsad M, Schiavina R, Castellucci P, et al: Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-1649.
16. Kwee SA, Coel MN, Lim J, Ko JP: Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005;173:252-255.
17. Bott SR: Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7:211-216.
18. Tiguert R, Gheiler EL, Tefilli MV, et al: Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999;53:367-371.
19. Kotzerke J, Prang J, Neumaier B, et al: Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-1419.
20. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-38;discussion 38-39.
21. 11C]choline- positron emission tomography for restaging prostate cancer: a comparison with 18F fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-1340.
22. Reske SN, Blumstein NM, Glatting G: PET and PET/CT in relapsing prostate carcinoma. Urologe [A] 2006;45:1240, 1242-1244, 1246-1248, 1250.
23. Scattoni V, Picchio M, Suardi N, et al: Detection of lymph-node metastases with integrated [(11)C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007;52:423-429.
24. Zeisel SH: Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981;1:95-121.
25. Reske SN, Blumstein NM, Neumaier B, et al: Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-1254.
26. 11C-choline positron emission tomography. Eur Urol 2002;42:18-23.
27. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-111.
28. 18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11:4761-4769.
29. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004;31:312-316.
30. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM: Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-3603.
31. Coleman R, DeGrado T, Wang S, et al: Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147.
32. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy. BJU Int 2007;99:1415-1420.
33. Piert M, Burian M, Meisetschlager G, et al: Positron detection for the intraoperative localisation of cancer deposits. Eur J Nucl Med Mol Imaging 2007;34:1534-1544.